In:
International Journal of Cancer, Wiley, Vol. 136, No. 5 ( 2015-03), p. 1085-1094
Abstract:
What's new? Dendritic cells (DCs) can activate an immune response by ‘presenting’ specific antigens on their surface. In this study, the authors found that when tumor cells are coated with therapeutic antibodies (mAbs), natural killer (NK) cells are activated to trigger the presentation of tumor antigens by special subsets of DCs. They also found that IFN‐γ and TNF‐α are crucial to this process. These results support the concept that NK cells can contribute to the efficacy of therapeutic mAbs by inducing anti‐tumor adaptive immunity.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink